Trials / Completed
CompletedNCT02039817
PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Severe Renal Impairment and in Matched Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Conatus Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, parallel-group study to compare the pharmacokinetics and pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with severe renal impairment and matched healthy volunteers with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDN-6556 |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2014-01-20
- Last updated
- 2016-01-28
- Results posted
- 2016-01-28
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02039817. Inclusion in this directory is not an endorsement.